ClinicalTrials.gg
TerminatedNCT04783389Updated Oct 17, 2023Results posted

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

A Phase 2 interventional study of CBP-201 and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Connect Biopharm LLC. Terminated at 68 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
44th of 71
40 · median 60
Started
2021
with 5 others
Phase 2
15 of 83
none open now
Registered
52nd of 83
by date

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 44th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2021, is one of 15 in phase 2, and was the 52nd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effect of CBP-201, rademikibart, in adult patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of CBP-201 on a background of mometasone furoate nasal spray (MFNS) in reducing endoscopic nasal polyp score (NPS) and nasal congestion/obstruction score (NCS) severity in eligible patients with CRSwNP whose disease remains inadequately controlled despite daily treatment with intranasal corticosteroid (INCS) therapy in comparison to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment period of 24 weeks and a follow-up period of 8 weeks.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients aged ≥ 18 and ≤ 75 years at the time of screening.
  2. Patients who are diagnosed with chronic rhinosinusitis with bilateral polyps despite treatment with systemic within the past 2 years and/or medical /intolerance to systemic corticosteroids. The polyps have a minimum bilateral nasal polyps score (NPS) of 5 out of a maximum score of 8 with at least a score of 2 for each nostril at screening and baseline evaluated by endoscopy.
  3. Nasal congestion/blockade/obstruction with moderate or severe symptom severity (Nasal Congestion Score of > 2) at screening and a weekly average severity of > 1 at time of randomization.
  4. Patients using a documented stable dose of nasal mometasone at least 200 mcg/day, or an equivalent daily dose of another inhaled nasal corticosteroid (INCS), for at least 28 days before randomization and willing to continue the dose for the duration of the study. Note: For patients who are using an alternative INCS product other than mometasone furoate nasal spray (MFNS) prior to the screening visit, the investigator must switch the patient to MFNS at V1.
  5. Patients willing to enter Patient Diary daily symptom assessments and maintain stable dosing with MFNS with a compliance of at least 70% in the 7 days preceding randomization. Note: Patients must use nasal mometasone at least 200 mcg/day, or equivalent, for at least 28 days before randomization, which can include days prior to screening with supportive documentation. Run-in can be 7-31 days with the compliance determined in the week prior to dosing.
  6. Male patients who are non-sterilized and sexually active with a female partner of agree to use highly effective from randomization until 8 weeks after last dose.
  7. Female patients of childbearing potential who are sexually active with a nonsterilized male partner should have a confirmed negative serum beta-human chorionic gonadotropin test at Visit 1 and agrees to use highly effective contraception from signing of throughout the duration of the study and for 8 weeks after last dose.
  8. Patient is able to understand and willing to sign the informed consent form (ICF) prior to any study related procedures being performed.
  9. Willing and able to comply with all study visits and study-related procedures, in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

-

A patient who meets any of the following criteria will be ineligible to participate in this study:

  1. Patients unable to use MFNS.
  2. Patients who are taking or have taken the following prohibited therapies as specified:

    1. Systemic within 28 days prior to screening,
    2. Other nonbiologic drugs within 60 days (or 5 half-lives, whichever is longer) of screening,
    3. Intranasal corticosteroid drops or corticosteroid-administering devices (eg, OptiNose device or stents) within 28 days prior to screening,
    4. Non-steroidal (eg, cyclosporine, methotrexate, azathioprine, mycophenolate, sirolimus, tacrolimus) within 60 days or 5 half-lives, whichever is longer, of screening,
    5. Any monoclonal antibody therapy (eg, benralizumab, mepolizumab, omalizumab, reslizumab, dupilumab) or investigational biologic drug for asthma or other diseases within 60 days or 5 half-lives, whichever is longer, of screening,
    6. Leukotriene antagonists/modifiers within 7 days prior to screening for patients who were not on continuous treatment for ≥ 30 days prior to screening,
    7. Allergen immunotherapy for patients who were not on maintenance treatment for at least 90 days prior to screening
  3. Patients who did not respond favorably to previous dupilumab treatment (eg, therapy failure or patient experienced an adverse reaction to treatment).
  4. Patients who have undergone any nasal surgery (including polypectomy) within 6 months before screening; or have a history of sinus or nasal surgery modifying the structure of the nose such that assessment of NPS is not possible, or have had uncontrolled epistaxis requiring surgical or procedural intervention, including nasal packing.
  5. Patients with conditions/concomitant diseases making them non evaluable at screening or for the primary efficacy endpoint such as: antrochoanal polyps, nasal septal deviation that would occlude at least 1 nostril, acute sinusitis, nasal infection or upper respiratory infection at screening or within 2 weeks before screening, ongoing rhinitis medicamentosa; known or suspected diagnosis of cystic fibrosis; chronic granulomatous disease and granulomatous vasculitis, granulomatosis with polyangiitis (Wegener's Granulomatosis), eosinophilic granulomatous with polyangiitis (Churg-Strauss syndrome), Young's syndrome, primary dyskinetic ciliary syndromes (eg, Kartagener's syndrome) or other dyskinetic ciliary syndromes.
  6. Signs or a CT scan suggestive of Allergic Fungal Rhinosinusitis.
  7. Patients with co-morbid asthma are excluded if:

    1. (FEV1) ≤ 50% of normal predicted value OR
    2. An exacerbation within 90 days prior screening that required hospitalization (> 24 hours) OR
    3. Are on a daily dose of inhaled corticosteroids (ICS) higher than 1000 mcg fluticasone or the equivalent.
  8. Known or suspected history of immunosuppression, including history of invasive opportunistic infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, (HIV), listeriosis, pneumocystosis, or tuberculosis, despite infection resolution; or unusually frequent, recurrent or prolonged infections. Tuberculosis testing would be performed on a country-by-country basis according to local guidelines if required by regulatory authorities or ethics committees.
  9. Patients who have active , or HIV infections as determined by positive results at Screening for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb); or hepatitis C (HCV) antibody; or positive HIV serology. Note: Patients who test positive for HBvAb, negative for HBsAg and subsequently confirmed positive for HBsAb, indicating resolved natural infection (confirmed by negative HBV-DNA), may participate. Patients with positive HCV may participate if subsequent viral load is confirmed negative.
  10. A helminth parasitic infection diagnosed within 24 weeks prior to the date of that has not been treated, or has failed to respond to, standard of care therapy.
  11. Evidence of infection requiring treatment with systemic antibacterials, antivirals, antifungals, antiparasitics, or antiprotozoals within 7 days before baseline, or viral infections within 14 days before screening that may not have received antiviral treatment.
  12. Live, attenuated vaccinations within 28 days prior to screening or planned live, attenuated vaccinations during the study.
  13. Pregnant or intent to become pregnant during the study, or breast-feeding women.
  14. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and may affect the safety of the patient throughout the study, or influence the findings of the studies or their interpretations, or impede the patient's ability to complete the entire duration of study.
  15. Any abnormal findings in physical examination, vital signs, safety lab tests during screening/run-in period, which in the opinion of the investigator, may put the patient at risk because of their participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.
  16. Have any of the following laboratory abnormalities at Screening:

    1. Eosinophils >1500 cells/mm3 (or 1.5 x 10E9/L)
    2. \<100000 cells/mm3 (or 100 x 10E9/L)
    3. Creatine phosphokinase (CPK) > 10 (ULN)
    4. (ALT) > 2.5 times the ULN
    5. Aspartate aminotransferase (AST) ≥ 2.5 times the ULN
    6. ≥ 2 times the ULN
  17. History of alcohol or drug abuse within 12 months prior to the date informed consent.
  18. An allergy to L-histidine, trehalose or Tween (polysorbate) 80 or a history of a systemic reaction, other than localized injection site reaction, to any biologic drug.
  19. Plans to undergo any surgical procedure requiring general anesthesia during the study.
  20. History of cancer: Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent. Note: Patients who have had other are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date of informed consent.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    CBP-201 Dose 1

    CBP-201 Dose 1 subcutaneous (SC) injection.

    Drug: CBP-201

  • Experimental
    CBP-201 Dose 2

    CBP-201 Dose 2 subcutaneous (SC) injection.

    Drug: CBP-201

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • CBP-201 subcutaneous (SC) injection.

    Also known as: rademikibart

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Change in Endoscopic Nasal Polyp Score (NPS)

    Change from baseline at Week 24 in endoscopic Nasal Polyp Score (NPS). Endoscopic NPS is assessed by central clinical specialist assessment of video recordings of nasal endoscopy. NPS is graded based on polyp size (recorded as the sum of the right and left nostril scores with a range of 0 to 8; higher scores indicate worse status). The scoring for each nostril is as follows: 0 No polyps, 1 Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate, 2 Polyps reaching below the lower border of the middle turbinate, 3 Large polyps reaching the lower border of the inferior turbinate or large polyps medial to the middle turbinate (i.e., reaching below the middle turbinate), 4 Large polyps causing complete obstruction of the inferior nasal cavity (i.e., touching the floor of the nose). The most improvement improvement possible from baseline would be -8 and the max worsening possible is +8.

    Time frame: From Baseline to Week 24

  2. Change in Average Daily Nasal Congestion Score (NCS)

    Change from baseline at Week 24 in average daily Nasal Congestion Score (NCS). Daily NCS wase assessed by patient diary from screening and throughout the study by using a 0 to 3 categorical scale for severity of symptoms from none to severe over the past 24 hours. The patient diary prompt: "How would you rate nasal congestion over the last 24 hours?" The answers are: 0 None,1 Minor, 2 Moderate, 3 Severe. The lowest possible weekly average is 0 and the highest possible is 3. The higher the NCS score, the worse the symptoms. Change from baseline in weekly average score is the outcome. Maximal improvement in NCS would be -3 and maximal worsening would be +3.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Change in Percentage of Maxillary Sinus Volume Occupied by Disease

    CT change from baseline at Week 24 in Lund-Mackay Computed Tomography scores. To calculate the Lund-Mackay score on a CT scan of the paranasal sinuses and ostiomeatal complex, the central blinded reader assigns each sinus a score from 0-2: 0 (no abnormality), 1 (partial opacification) or 2 (complete opacification). The ostiomeatal complex is assigned a score of either 0 (not obstructed) or 2 (obstructed).The sinuses are grouped into: frontal sinus, anterior ethmoidal cells, posterior ethmoidal cells, maxillary sinus, sphenoid sinus, ostiomeatal complex. Each side is graded separately. A combined score from 0 to 24 is possible with 0 being no abnormality and 24 being complete obstruction. The maximal possible change from baseline score would be -24 and the maximal worsening from baseline score would be +24.

    Time frame: From Baseline to Week 24

  2. Change in University of Pennsylvania Smell Identification Test (UPSIT)

    Change from baseline at Week 24 in University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a commercially available, validated, "scratch and sniff" smell test that has 40 items, where each item has 1 correct answer and 3 incorrect answers or "distractors". An UPSIT result is scored out of 40 where a higher score indicates better olfaction (maximum being 40) and 0 indicates the worst possible olfaction outcome. The maximal possible improvement from baseline would be +40 and the worst possible change from baseline would be a score of -40.

    Time frame: From Baseline to Week 24

  3. Change in Visual Analogue Scale for Rhinosinusitis (VAS-RS)

    Change from baseline at Week 24 in Visual Analogue Scale for Rhinosinusitis (VAS-RS). The Visual Analogue Scale for Rhinosinusitis (VAS-RS) is a 10 cm linear scale that ranges from "none" to "more than I can imagine" for each of 14 defined nasal symptoms (runny nose, loss of smell, etc). The VAS instructions direct the patient to mark a vertical line at the point that best corresponds to how bothersome their symptoms have been between visits the VAS-RS is collected. Site staff measure the distance from none to the patient's mark for each of the 14 symptoms and adds the total number of cm. The least possible score is 0 reflecting no symptoms and the maximal score is 140 reflecting the worst possible symptoms. The best possible outcome change from baseline to week 24 would be a score of -140 and the worst possible change from baseline score would be +140.

    Time frame: From Baseline to Week 24

  4. Change in Total Nasal Symptom Score (TNSS)

    Change from baseline at Week 24 in Total Nasal Symptom Score (TNSS). The Total Nasal Symptom Score is a Patient Reported Outcome which is a total of 3 sub-question scores which are scored 0-3 (0=no symptoms, 1=mild, 2=moderate, 3=severe) for Nasal Obstruction, Itching/Sneezing, and Secretion/Runny Nose. The total possible TNSS score is 9 representing the worst symptoms and the a score of 0 represents no symptoms. The worst change from baseline to Week 24 would be a score of +9 and the best possible change from baseline score would be -9.

    Time frame: From Baseline to Week 24

  5. Change in 22-item Sinonasal Outcome Test (SNOT-22)

    Change from baseline at Week 24 in 22-item Sinonasal Outcome Test (SNOT-22) The Sino-Nasal Outcome Test (SNOT-22) is a 22-item list of symptoms and social/emotional consequences related to the patient's rhinosinusitis, using a 5-point scale (0,1,2,3,4,5), where score of 0 indicates No Problem, 2 for Very Mild Problem, 3 for Mild or Slight Problem, 4 for Moderate Problem, and 5 for Problem as bad as it can be. The SNOT-22 score range is 0-110, with higher scores representing worse symptoms associated with disease. A maximum improvement or outcome from baseline would be -110 and a maximum worsening of symptoms from baseline would be +110.

    Time frame: From Baseline to Week 24

  6. Change in Average Daily Anterior Rhinorrhea Score

    Change from baseline at Week 24 in average daily anterior rhinorrhea score. Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your anterior rhinorrhea (the discharge draining from your nose, "runny nose") in the past 24 hours?" The participant entered a score from 0-4: 0 No noticeable discharge from my nose; 1 Minor discharge from my nose, did not require tissues; 2 Some discharge from my nose, required a few tissues; 3 Significant discharge from my nose; 4 Near constant discharge from my nose. The higher the score the worse the outcome with a range of 0-4. The maximum improvement in weekly average of daily symptoms was -4 and the maximal worsening in symptoms was +4.

    Time frame: From Baseline to Week 24

  7. Change in Average Daily Posterior Rhinorrhea Score

    Change from baseline at Week 24 in average daily posterior rhinorrhea score. Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your posterior rhinorrhea (postnasal phlegm dripping into your throat) in the past 24 hours?" The participant entered a score from 0-4: 0 No noticeable postnasal drip; 1 Some minor postnasal drip; 2 Moderate postnasal drip; 3 Significant postnasal drip; 4 Near constant postnasal drip. The higher the score the worse the outcome with a range of 0-4. The maximum improvement in weekly average of daily symptoms was -4 and the maximal worsening in symptoms was +4.

    Time frame: From Baseline to Week 24

  8. Change in Average Daily Loss of Smell Score

    Change from baseline at Week 24 in average daily loss of smell score Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your ability to smell?" The participant entered a score from 0-3: 0 Not able to smell anything; 1 Can smell only strong odors; 2 Can smell some, but not all, odors; 3 Have no problem smelling The maximum improvement in weekly average of daily symptoms was +3 and the maximal worsening in symptoms was -3.

    Time frame: From Baseline to Week 24

  9. Change in Daily Subject-assessed Nasal Peak Inspiratory Flow (NPIF)

    Change from baseline at Week 24 in daily subject-assessed nasal peak inspiratory flow (NPIF). Participants performed a nasal peak inspiratory flow (NPIF) maneuver twice daily at home and recorded the result on an electronic diary device. An improvement in flow rate (L/min) is considered an improvement and a decrease in flow rate is considered a worsening of symptoms. A change from baseline improvement in flow rate would be a positive number and a worsening from baseline would be a negative number. MCID is considered to be a change from baseline of approximately 20 L/min.

    Time frame: From Baseline to Week 24

  10. Change From Baseline in Blood Level of IgE

    Change from baseline will be summarized with descriptive statistics in blood level of IgE. IgE (ng/mL) was measured in blood samples sent to a central clinical laboratory. A negative change from baseline will be considered a clinical improvement and a positive change from baseline will be considered a lack of improvement.

    Time frame: From Baseline to Week 32

  11. Change From Baseline in Peripheral Eosinophil Counts

    Change from baseline will be summarized with descriptive statistics in peripheral eosinophil counts. Eosinophil counts in the blood (reported as 10\^9/L) were determined from blood samples sent to a central clinical laboratory. A negative change from baseline will be considered a clinical improvement and a positive change from baseline will be considered a lack of clinical improvement.

    Time frame: From Baseline to Week 32

  12. Change From Baseline in Eosinophil Cationic Protein (ECP)

    Change from baseline will be summarized with descriptive statistics in eosinophil cationic protein (ECP). Eosinophil cationic protein (reported as ng/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. An decrease in ECP will be considered an improvement in outcome and an increase will be considered a lack of improvement in clinical outcome.

    Time frame: From Baseline to Week 32

  13. Change From Baseline in Thymus and Activation-regulated Chemokine (TARC)

    Change from baseline will be summarized with descriptive statistics in thymus and activation-regulated chemokine (TARC). TARC (reported in pg/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease in TARC will be considered an improvement in clinical outcome and an increase in TARC will be considered a lack of clinical improvement.

    Time frame: From Baseline to Week 32

  14. Change From Baseline in Eotaxin-3

    Change from baseline will be summarized with descriptive statistics in Eotaxin-3. Eotaxin-3 (reported in pg/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease from baseline will be considered a clinically improvement and an increase will be considered a lack of improvement.

    Time frame: From Baseline to Week 32

  15. Change From Baseline in Periostin

    Change from baseline will be summarized with descriptive statistics in periostin. Periostin (reported in ng/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease from baseline will be considered a positive clinical outcome and an increase will be be considered to lack a positive outcome.

    Time frame: From Baseline to Week 32

07

Results

Posted Oct 17, 2023
Limitations and caveats
The study was prematurely discontinued after 40 patients were enrolled due to recruitment issues resulting from the COVID-19 pandemic and operational issues such as the inability to fully conduct/implement the study (e.g., monitoring, logistics of drug supply, transportation of clinical testing samples, etc.) due to the Russian invasion of Ukraine in Mar 2022. Because only limited data was collected, no definitive conclusions can be made at the pre-planned 24-week primary endpoint.

Participant flow

Participant flow — Overall Study
MilestoneCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Started131314
Completed110
Not completed121214
Withdrew: Withdrawal by subject200
Withdrew: Termination of study by sponsor101214

Outcome measures

PrimaryChange in Endoscopic Nasal Polyp Score (NPS)

Change from baseline at Week 24 in endoscopic Nasal Polyp Score (NPS). Endoscopic NPS is assessed by central clinical specialist assessment of video recordings of nasal endoscopy. NPS is graded based on polyp size (recorded as the sum of the right and left nostril scores with a range of 0 to 8; higher scores indicate worse status). The scoring for each nostril is as follows: 0 No polyps, 1 Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate, 2 Polyps reaching below the lower border of the middle turbinate, 3 Large polyps reaching the lower border of the inferior turbinate or large polyps medial to the middle turbinate (i.e., reaching below the middle turbinate), 4 Large polyps causing complete obstruction of the inferior nasal cavity (i.e., touching the floor of the nose). The most improvement improvement possible from baseline would be -8 and the max worsening possible is +8.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in Endoscopic Nasal Polyp Score (NPS)
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg Q4WPlacebo
Change in Endoscopic Nasal Polyp Score (NPS)0 ± NA——
PrimaryChange in Average Daily Nasal Congestion Score (NCS)

Change from baseline at Week 24 in average daily Nasal Congestion Score (NCS). Daily NCS wase assessed by patient diary from screening and throughout the study by using a 0 to 3 categorical scale for severity of symptoms from none to severe over the past 24 hours. The patient diary prompt: "How would you rate nasal congestion over the last 24 hours?" The answers are: 0 None,1 Minor, 2 Moderate, 3 Severe. The lowest possible weekly average is 0 and the highest possible is 3. The higher the NCS score, the worse the symptoms. Change from baseline in weekly average score is the outcome. Maximal improvement in NCS would be -3 and maximal worsening would be +3.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in Average Daily Nasal Congestion Score (NCS)
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Average Daily Nasal Congestion Score (NCS)-0.8571 ± 1.4142-1.8000—
SecondaryChange in Percentage of Maxillary Sinus Volume Occupied by Disease

CT change from baseline at Week 24 in Lund-Mackay Computed Tomography scores. To calculate the Lund-Mackay score on a CT scan of the paranasal sinuses and ostiomeatal complex, the central blinded reader assigns each sinus a score from 0-2: 0 (no abnormality), 1 (partial opacification) or 2 (complete opacification). The ostiomeatal complex is assigned a score of either 0 (not obstructed) or 2 (obstructed).The sinuses are grouped into: frontal sinus, anterior ethmoidal cells, posterior ethmoidal cells, maxillary sinus, sphenoid sinus, ostiomeatal complex. Each side is graded separately. A combined score from 0 to 24 is possible with 0 being no abnormality and 24 being complete obstruction. The maximal possible change from baseline score would be -24 and the maximal worsening from baseline score would be +24.

Time frame:
From Baseline to Week 24

No measurements were reported for this outcome.

SecondaryChange in University of Pennsylvania Smell Identification Test (UPSIT)

Change from baseline at Week 24 in University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a commercially available, validated, "scratch and sniff" smell test that has 40 items, where each item has 1 correct answer and 3 incorrect answers or "distractors". An UPSIT result is scored out of 40 where a higher score indicates better olfaction (maximum being 40) and 0 indicates the worst possible olfaction outcome. The maximal possible improvement from baseline would be +40 and the worst possible change from baseline would be a score of -40.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in University of Pennsylvania Smell Identification Test (UPSIT)
score on a scaleCBP-201 300 mg Q2WCBP-201 300 mg Q4WPlacebo
Change in University of Pennsylvania Smell Identification Test (UPSIT)613—
SecondaryChange in Visual Analogue Scale for Rhinosinusitis (VAS-RS)

Change from baseline at Week 24 in Visual Analogue Scale for Rhinosinusitis (VAS-RS). The Visual Analogue Scale for Rhinosinusitis (VAS-RS) is a 10 cm linear scale that ranges from "none" to "more than I can imagine" for each of 14 defined nasal symptoms (runny nose, loss of smell, etc). The VAS instructions direct the patient to mark a vertical line at the point that best corresponds to how bothersome their symptoms have been between visits the VAS-RS is collected. Site staff measure the distance from none to the patient's mark for each of the 14 symptoms and adds the total number of cm. The least possible score is 0 reflecting no symptoms and the maximal score is 140 reflecting the worst possible symptoms. The best possible outcome change from baseline to week 24 would be a score of -140 and the worst possible change from baseline score would be +140.

Time frame:
From Baseline to Week 24
Reported as:
Mean · units on a scale
Change in Visual Analogue Scale for Rhinosinusitis (VAS-RS)
units on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Visual Analogue Scale for Rhinosinusitis (VAS-RS)-33.00-29.70—
SecondaryChange in Total Nasal Symptom Score (TNSS)

Change from baseline at Week 24 in Total Nasal Symptom Score (TNSS). The Total Nasal Symptom Score is a Patient Reported Outcome which is a total of 3 sub-question scores which are scored 0-3 (0=no symptoms, 1=mild, 2=moderate, 3=severe) for Nasal Obstruction, Itching/Sneezing, and Secretion/Runny Nose. The total possible TNSS score is 9 representing the worst symptoms and the a score of 0 represents no symptoms. The worst change from baseline to Week 24 would be a score of +9 and the best possible change from baseline score would be -9.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in Total Nasal Symptom Score (TNSS)
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Total Nasal Symptom Score (TNSS)-2-2—
SecondaryChange in 22-item Sinonasal Outcome Test (SNOT-22)

Change from baseline at Week 24 in 22-item Sinonasal Outcome Test (SNOT-22) The Sino-Nasal Outcome Test (SNOT-22) is a 22-item list of symptoms and social/emotional consequences related to the patient's rhinosinusitis, using a 5-point scale (0,1,2,3,4,5), where score of 0 indicates No Problem, 2 for Very Mild Problem, 3 for Mild or Slight Problem, 4 for Moderate Problem, and 5 for Problem as bad as it can be. The SNOT-22 score range is 0-110, with higher scores representing worse symptoms associated with disease. A maximum improvement or outcome from baseline would be -110 and a maximum worsening of symptoms from baseline would be +110.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in 22-item Sinonasal Outcome Test (SNOT-22)
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in 22-item Sinonasal Outcome Test (SNOT-22)-17-6—
SecondaryChange in Average Daily Anterior Rhinorrhea Score

Change from baseline at Week 24 in average daily anterior rhinorrhea score. Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your anterior rhinorrhea (the discharge draining from your nose, "runny nose") in the past 24 hours?" The participant entered a score from 0-4: 0 No noticeable discharge from my nose; 1 Minor discharge from my nose, did not require tissues; 2 Some discharge from my nose, required a few tissues; 3 Significant discharge from my nose; 4 Near constant discharge from my nose. The higher the score the worse the outcome with a range of 0-4. The maximum improvement in weekly average of daily symptoms was -4 and the maximal worsening in symptoms was +4.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in Average Daily Anterior Rhinorrhea Score
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Average Daily Anterior Rhinorrhea Score-0.61 ± 1.273-1.25—
SecondaryChange in Average Daily Posterior Rhinorrhea Score

Change from baseline at Week 24 in average daily posterior rhinorrhea score. Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your posterior rhinorrhea (postnasal phlegm dripping into your throat) in the past 24 hours?" The participant entered a score from 0-4: 0 No noticeable postnasal drip; 1 Some minor postnasal drip; 2 Moderate postnasal drip; 3 Significant postnasal drip; 4 Near constant postnasal drip. The higher the score the worse the outcome with a range of 0-4. The maximum improvement in weekly average of daily symptoms was -4 and the maximal worsening in symptoms was +4.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in Average Daily Posterior Rhinorrhea Score
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Average Daily Posterior Rhinorrhea Score-0.66 ± 0.4850.25—
SecondaryChange in Average Daily Loss of Smell Score

Change from baseline at Week 24 in average daily loss of smell score Participants reported symptoms daily on an electronic diary. The diary prompt was "How would you rate your ability to smell?" The participant entered a score from 0-3: 0 Not able to smell anything; 1 Can smell only strong odors; 2 Can smell some, but not all, odors; 3 Have no problem smelling The maximum improvement in weekly average of daily symptoms was +3 and the maximal worsening in symptoms was -3.

Time frame:
From Baseline to Week 24
Reported as:
Mean · score on a scale
Change in Average Daily Loss of Smell Score
score on a scaleCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Average Daily Loss of Smell Score0.750 ± 0.58930.8571—
SecondaryChange in Daily Subject-assessed Nasal Peak Inspiratory Flow (NPIF)

Change from baseline at Week 24 in daily subject-assessed nasal peak inspiratory flow (NPIF). Participants performed a nasal peak inspiratory flow (NPIF) maneuver twice daily at home and recorded the result on an electronic diary device. An improvement in flow rate (L/min) is considered an improvement and a decrease in flow rate is considered a worsening of symptoms. A change from baseline improvement in flow rate would be a positive number and a worsening from baseline would be a negative number. MCID is considered to be a change from baseline of approximately 20 L/min.

Time frame:
From Baseline to Week 24
Reported as:
Mean · L/min
Change in Daily Subject-assessed Nasal Peak Inspiratory Flow (NPIF)
L/minCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change in Daily Subject-assessed Nasal Peak Inspiratory Flow (NPIF)46.5714 ± 66.8721152.5000—
SecondaryChange From Baseline in Blood Level of IgE

Change from baseline will be summarized with descriptive statistics in blood level of IgE. IgE (ng/mL) was measured in blood samples sent to a central clinical laboratory. A negative change from baseline will be considered a clinical improvement and a positive change from baseline will be considered a lack of improvement.

Time frame:
From Baseline to Week 32
Reported as:
Mean · ng/mL
Change From Baseline in Blood Level of IgE
ng/mLCBP-201 300 mg SC Q2WCBP-201 300 SC Q4WPlacebo
Change From Baseline in Blood Level of IgE-35794.02——
SecondaryChange From Baseline in Peripheral Eosinophil Counts

Change from baseline will be summarized with descriptive statistics in peripheral eosinophil counts. Eosinophil counts in the blood (reported as 10\^9/L) were determined from blood samples sent to a central clinical laboratory. A negative change from baseline will be considered a clinical improvement and a positive change from baseline will be considered a lack of clinical improvement.

Time frame:
From Baseline to Week 32
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Peripheral Eosinophil Counts
10^9 cells/LCBP-201 300 mg Q2WCBP-201 300 mg SC Q4WPlacebo
Change From Baseline in Peripheral Eosinophil Counts0.30——
SecondaryChange From Baseline in Eosinophil Cationic Protein (ECP)

Change from baseline will be summarized with descriptive statistics in eosinophil cationic protein (ECP). Eosinophil cationic protein (reported as ng/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. An decrease in ECP will be considered an improvement in outcome and an increase will be considered a lack of improvement in clinical outcome.

Time frame:
From Baseline to Week 32
Reported as:
Mean · ng/mL
Change From Baseline in Eosinophil Cationic Protein (ECP)
ng/mLCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change From Baseline in Eosinophil Cationic Protein (ECP)-20.68——
SecondaryChange From Baseline in Thymus and Activation-regulated Chemokine (TARC)

Change from baseline will be summarized with descriptive statistics in thymus and activation-regulated chemokine (TARC). TARC (reported in pg/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease in TARC will be considered an improvement in clinical outcome and an increase in TARC will be considered a lack of clinical improvement.

Time frame:
From Baseline to Week 32

No measurements were reported for this outcome.

SecondaryChange From Baseline in Eotaxin-3

Change from baseline will be summarized with descriptive statistics in Eotaxin-3. Eotaxin-3 (reported in pg/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease from baseline will be considered a clinically improvement and an increase will be considered a lack of improvement.

Time frame:
From Baseline to Week 32
Reported as:
Mean · pg/mL
Change From Baseline in Eotaxin-3
pg/mLCBP-201 300 SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change From Baseline in Eotaxin-30.040——
SecondaryChange From Baseline in Periostin

Change from baseline will be summarized with descriptive statistics in periostin. Periostin (reported in ng/mL) was measured in blood samples collected from participants and sent to a central clinical laboratory for processing. A decrease from baseline will be considered a positive clinical outcome and an increase will be be considered to lack a positive outcome.

Time frame:
From Baseline to Week 32
Reported as:
Mean · ng/mL
Change From Baseline in Periostin
ng/mLCBP-201 300 mg SC Q2WCBP-201 300 mg SC Q4WPlacebo
Change From Baseline in Periostin106.52——

Adverse events

Collected over Both AEs and SAEs were recorded from the time the patient signs the ICF until Visit 17 (32 weeks) or Early Termination Visit, whichever occured first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CBP-201 300 mg Q2W0/13 (0%)0/13 (0%)1/13 (7.7%)
CBP-201 Dose 20/13 (0%)0/13 (0%)3/13 (23.1%)
Placebo0/14 (0%)0/14 (0%)1/14 (7.1%)
Most frequent other events
Most frequent other events
EventCBP-201 300 mg Q2WCBP-201 Dose 2Placebo
Injection site erythemaGeneral disorders1/131/130/14
Injection site oedemaGeneral disorders0/131/130/14
Injection site pruritisGeneral disorders0/131/130/14
MigraineNervous system disorders0/131/130/14
Blood creatine phosphokinase increasedInvestigations0/131/130/14
DizzinessNervous system disorders0/130/131/14
Abdominal painGastrointestinal disorders0/130/131/14
VomitingGastrointestinal disorders0/130/131/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
<=18 years0000
Between 18 and 65 years10121032
>=65 years3148
Age, Continuous
Age, Continuous(years)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
Mean53.0 ± 14.8047.3 ± 11.3547.9 ± 17.9649.4 ± 14.65
Sex: Female, Male
Sex: Female, Male(Participants)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
Female25512
Male118928
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
Hispanic or Latino1113
Not Hispanic or Latino12121337
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
American Indian or Alaska Native0000
Asian74415
Native Hawaiian or Other Pacific Islander0000
Black or African American2002
White491023
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
United States57820
China74415
Poland1225
Nasal Polyp Score
Nasal Polyp Score(units on a scale)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
Mean5.5 ± 1.735.5 ± 1.385.6 ± 1.565.5 ± 1.52
Nasal Congestion Score (NCS)
Nasal Congestion Score (NCS)(units on a scale)CBP-201 300 mg SC Q2WCBP-201 Dose 2PlaceboTotal
Mean2.4945 ± 0.53652.1429 ± 0.59192.4507 ± 0.50902.3649 ± 0.5544

2 further baseline measures are reported on the registry.

08

Study locations

68 sites
  • Connect Investigative Site 130
    Birmingham, Alabama 35205, United States
  • Connect Investigative Site 124
    Bakersfield, California 93301, United States
  • Connect Investigative Site 125
    La Mesa, California 91942, United States
  • Connect Investigative Site 134
    Los Angeles, California 90048, United States
  • Connect Investigative Site 128
    Temecula, California 92592, United States
  • Connect Investigative Site 119
    Torrance, California 90503, United States
  • Connect Investigative Site 114
    Miami, Florida 33135, United States
  • Connect Investigative Site 109
    Miami, Florida 33155, United States
  • Connect Investigative Site 116
    Tampa, Florida 33613, United States
  • Connect Investigative Site 111
    Chicago, Illinois 60637, United States
  • Connect Investigative Site 126
    Chicago, Illinois 60657, United States
  • Connect Investigative Site 132
    Louisville, Kentucky 40205, United States
  • Connect Investigative Site 110
    White Marsh, Maryland 21162, United States
  • Connect Investigative Site 121
    Ann Arbor, Michigan 48109-0360, United States
  • Connect Investigative Site 127
    Saint Louis, Missouri 63141, United States
  • Connect Investigative Site 102
    Princeton, New Jersey 08540, United States
  • Connect Investigative Site 113
    Bronx, New York 10461, United States
  • Connect Investigative Site 105
    Rochester, New York 14618, United States
  • Connect Investigative Site 117
    Winston-Salem, North Carolina 27103, United States
  • Connect Investigative Site 123
    Cincinnati, Ohio 45229, United States
  • Connect Investigative Site 133
    Columbus, Ohio 43235, United States
  • Connect Investigative Site 112
    Tulsa, Oklahoma 74136, United States
  • Connect Investigative Site 122
    Tulsa, Oklahoma 74137, United States
  • Connect Investigative Site 108
    Charleston, South Carolina 29425, United States
  • Connect Investigative Site 107
    Memphis, Tennessee 38119, United States
  • Connect Investigative Site 106
    Austin, Texas 75759, United States
  • Connect Investigative Site 104
    Dallas, Texas 75231, United States
  • Connect Investigative Site 120
    Houston, Texas 77074, United States
  • Connect Investigative Site 101
    Sherman, Texas 75092, United States
  • Connect Investigative Site 129
    Saint George, Utah 84790, United States
  • Connect Investigative Site 118
    Norfolk, Virginia 23507, United States
  • Connect Investigative Site 115
    Bellingham, Washington 98225, United States
  • Connect Investigative Site 307
    Bengbu, Anhui 233060, China
  • Connect Investigative Site 303
    Chongqing, Chongqing 400042, China
  • Connect Investigative Site 302
    Nanning, Guangxi 530021, China
  • Connect Investigative Site 309
    Jingzhou, Hubei 434020, China
  • Connect Investigative Site 306
    Nanjing, Jiangsu 210029, China
  • Connect Investigative Site 308
    Yangzhou, Jiangsu 225007, China
  • Connect Investigative Site 313
    Shenyang, Liaoning 110004, China
  • Connect Investigative Site 304
    Qingdao, Shandong 266033, China
  • Connect Investigative Site 301
    Shanghai, Shanghai 200031, China
  • Connect Investigative Site 312
    Shanghai, Shanghai 201620, China
  • Connect Investigative Site 311
    Taiyuan, Shanxi 30001, China
  • Connect Investigative Site 305
    Xi'an, Shanxi 710061, China
  • Connect Investigative Site 310
    Hangzhou, Zhejiang 310014, China
  • Connect Investigative Site 409
    Lubin, Dolnoslaskie 59-300, Poland
  • Connect Investigative Site 401
    Bydgoszcz, Kujawsko-Pomorskie 85-605, Poland
  • Connect Investigative Site 407
    Kraków, Malopolskie 30-033, Poland
  • Connect Investigative Site 402
    Kraków, Malopolskie 31-411, Poland
  • Connect Investigative Site 403
    Warszawa, Masovian 02-793, Poland
  • Connect Investigative Site 408
    Warszawa, Mazowieckie 00-892, Poland
  • Connect Investigative Site 405
    Rzeszow, Podkarpackie 35-055, Poland
  • Connect Investigative Site 404
    Białystok, Podlaskie 15-879, Poland
  • Connect Investigative Site 406
    Zabrze, Slaskie 41-800, Poland
  • Connect Investigative Site 604
    Barcelona, Catalunya 08208, Spain
  • Connect Investigative Site 602
    Córdoba, Spain
  • Connect Investigative Site 601
    Madrid, 28040, Spain
  • Connect Investigative Site 603
    Sevilla, 41009, Spain
  • Connect Investigative Site 501
    Dnipropetrovsk, Dnipro 49006, Ukraine
  • Connect Investigative Site 507
    Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast' 76000, Ukraine
  • Connect Investigative Site 508
    Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast' 76000, Ukraine
  • Connect Investigative Site 510
    Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast' 76000, Ukraine
  • Connect Investigative Site 509
    Kharkiv, Kharkivska Oblast 61124, Ukraine
  • Connect Investigative Site 506
    Poltava, Poltavska Oblast 36038, Ukraine
  • Connect Investigative Site 504
    Lutsk, Volyns'ka Oblast' 43005, Ukraine
  • Connect Investigative Site 503
    Kyiv, 2002, Ukraine
  • Connect Investigative Site 502
    Kyiv, 3049, Ukraine
  • Connect Investigative Site 505
    Kyiv, 3057, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Apr 2022, 9 months.

Results were first posted in Oct 2023, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Mar 5, 2021
StartActual
Jun 16, 2021
Primary completionActual
Apr 15, 2022
CompletionActual
Jun 10, 2022
Results first posted
Oct 17, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04783389
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Jun 16, 2021
Primary completion
Apr 15, 2022
Completion
Jun 10, 2022
Results posted
Oct 17, 2023
Last update
Oct 17, 2023

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion